Notox Announces Appointment of Mary Kander to Medical Advisory Board

Richmond Hill, Ontario--(Newsfile Corp. - June 15, 2022) - Notox Technologies Corp. (OTC: NTOX) ("Notox" or the "Company") is pleased to announce the appointment of Mary Kander to the Company's Medical Advisory Board.

Ms. Kander is a Senior Consultant with Wave Strategy LLC, a consulting firm focused on providing expertise on technology commercialization to clients that include leading medical centers, academic institutions and early stage biotechnology entities. She is an expert in the development of new product concepts with prior roles that include 18 years of experience with Cleveland Clinic Innovations, most recently as the General Manager of Technology Commercialization. Ms. Kander was previously a Vice President at Invacare Corporation, where she was responsible for the Home Care Products group, and held various finance roles at Procter & Gamble.

Ms. Kander received her MBA from the University of North Carolina at Chapel Hill and her bachelor's degree from John Carroll University.

"As Notox continues its development process, I am extremely proud to announce that Mary Kander has agreed to join the Company's Medical Advisory Board," commented Zoran Konević, the Chairman and CEO of Notox. "We had the pleasure of working with Ms. Kander during her tenure at Cleveland Clinic Innovations, and know that she has the qualifications, experience and track record to benefit Notox and its shareholders. We look forward to Ms. Kander's contributions along with the other two members of our Medical Advisory Board, Dr. Frank Papay and Dr. Tyler Kendall."

About Notox Technologies Corp.

Notox Technologies Corp. (OTC: NTOX) is in the business of developing and commercializing innovative technologies primarily through its wholly owned Nevada subsidiary, Notox Bioscience Inc. The Company is seeking to build its distribution capabilities for medical and aesthetic products around the world, and to market a credible, non-toxic alternative to Botox and subsequently develop other features of its Notox technology such as drug-free pain management, body countering, skin tightening and anti-perspiration.

For more information, please contact:

Zoran Konević - Chairman & CEO
(519) 421-1900
info@hellonotox.com

Safe Harbor Statement and Forward-Looking Statements

This news release may contain forward-looking statements that involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements reflect the Company's current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, investors should not place undue reliance on these forward-looking statements. Such statements may include, but are not limited to, information related to: anticipated operating results; relationships with customers and strategic partners; consumer demand; financial resources and condition; the ability to list any securities for trading on a recognized exchange; changes in revenues; changes in profitability; changes in accounting treatment; changes in management; cost of sales; selling, general and administrative expenses; interest expense; the ability to produce the liquidity or enter into agreements to acquire the capital necessary to continue operations and take advantage of opportunities; and legal proceedings and claims. Except as required by law, the Company assumes no obligation to update any forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, even if new information becomes available in the future.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/127978